1.miR-375 promotes prostate cancer cell migration and invasion by targeting KLF4
Enshan PAN ; Yugang LI ; Xiaoguang ZHU
Chongqing Medicine 2017;46(23):3184-3188
Objective To explore the expression,role and mechanism of miR-375 in prostate cancer (PCa) cells.Methods PCa cells were cultured and transfected with plasmid,the migration and invasion of PCa were detected by Transwell;the expression of miR-375 and KLF4 mRNA were detected by qPCR;the expression of KLF4 were detect by Western blot;the potential target genes of miR-375 were analyzed by bioinformatics and verified by dual luciferase report.Results The expression of miR-375 were significantly up-regulated in the PCa;Inhibited the expression of miR-375 could significantly inhibit the migration and invasion of PCa cells.KLF4 was the potential target genes of miR-375,which verified through bioinformatics analysis and dual luciferase report.The expression of KLF4 were significantly down-regulated in the PCa.Inhibited the expression of miR-375 could significantly up-regulated the expression of KLF4.Inhibited the KLF4 expression was able to reverse the suppressive effect miR-375 has on the migration and invasion of PCa cells.Conclusion miR-375 promotes the migration and invasion of PCa via inhibiting the expression of KLF4 and play the oncogene role.MiR-375 can be used as therapeutic targets for PCa,and provide a new direction for the treatment of PCa.
2.HYBRIDOMA CELL LINES SECRETING MONOCLONAL ANTIBODIES AGAINST THE TYPE B TOXIN OF CLOSTRIDIUM BOTULINUM
Qiquan HUANG ; Meixian WANG ; Enshan LI ; Liangshou LI ; Shizhong ZHANG
Medical Journal of Chinese People's Liberation Army 1981;0(04):-
The spleen cells from the BALB/C mouse immunized with the type B toxoid were fused with aNS-1 myeloma cell line. The superatant containing the hybridoma-formed cells with growing pores wasscreened by EL1SA, in which 66.7% the pores could secrete the specific antibodies against botulin.After a Subclonizing culture by the limiting dilution technique four hybridoma cell lines(3B10, 3B11, 3G12 and 4A5) were established and could secrete the specific antibodies persistently in the culture medium. in which antibody titers came to 10-3-10-5, while they were injected into the BALB/C mice intrape ritoneally ascites rich in antibodies with a titer of 10-5-10-8 was produced. The results testing the (our monoclonal antibodies with the type A and B toxoids showed that the antibodies of 3G12and 4A5 were specific for the type B toxoid, and those of 3B10 and 3B11 had light cross reaction with the type A toxoid. Identification of 1g showed that the antibodies of 3B10 and 3G12 were of IgG1, while those of 3B11 and 4A5 of IgG2. The chromosomal assay confirmed the four cell lines to be hybridoma. The neutroligation test in mice revealed that those four monoclonal antibodies did not show any protective effects on botulin.
3.Clinical study of combined interventional embolization for the treatment of portal hypertention
Xuejian LIU ; Enshan LI ; Youping MA ; Chunqing ZHANG
Chinese Journal of General Surgery 1993;0(01):-
0.05).(4) Free pressure of portal vein(FPP) significantly declined at post-operation in the two groups(P
4.Effect of subtotal splenectomy with retroperitoneal splenic transposition and devascularization on portal hypertensive gastropathy
Enshan LI ; Liande ZHAO ; Lidong ZHU ; Qingxu SUN ; Zhengping LI ; Yuankai ZHANG
Chinese Journal of General Surgery 2001;0(08):-
Objective To study the effect of the modality of subtotal splenectomy with retroperitoneal splenic transposition combined with devascularization on portal hypertensive gastropahy(PHG). Methods Subtotal splenectomy with retroperitoneal splenic transposition combined with devascularization was performed in 48 cirrhotic patients with portal hypertension. Forty seven patients were followed up for 2 years to 13 years (average 91 months). PHG were observed by gastroscopy.Results At 2 months postoperation ,PHG was significantly aggravated compared with that of preoperation (P
5.Clinical features and genetic analysis of a patient with type 2 neurofibromatosis manifested as oculomotor nerve palsy.
Xinghuan DING ; Bo LIANG ; Tingyu LIANG ; Jingjing LI ; Fang WANG ; Enshan FENG
Chinese Journal of Medical Genetics 2023;40(7):851-855
OBJECTIVE:
To report on a rare case of Neurofibromatosis type 2 (NF2) manifesting as oculomotor nerve palsy and explore its genetic basis.
METHODS:
A patient with NF2 who had presented at Beijing Ditan Hospital Affiliated to Capital Medical University on July 10, 2021 was selected as the study subject. Cranial and spinal cord magnetic resonance imaging (MRI) was carried out on the patient and his parents. Peripheral blood samples were collected and subjected to whole exome sequencing. Candidate variant was verified by Sanger sequencing.
RESULTS:
MRI revealed bilateral vestibular Schwannomas, bilateral cavernous sinus meningiomas, popliteal neurogenic tumors, and multiple subcutaneous nodules in the patient. DNA sequencing revealed that he has harbored a de novo nonsense variant of the NF2 gene, namely c.757A>T, which has replaced a codon (AAG) encoding lysine (K) at position 253 with a stop codon (TAG). This has resulted in removal of the Merlin protein encoded by the NF2 gene from position 253 onwards. The variant was not found in public databases. Bioinformatic analysis suggested that the corresponding amino acid is highly conserved. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was rated as pathogenic (PVS1+PS2+PM2_Supporting+PP3+PP4).
CONCLUSION
The heterozygous nonsense variant c.757A>T (p.K253*) of the NF2 gene probably underlay the disease in this patient with an early onset, atypical but severe phenotype.
Male
;
Humans
;
Neurofibromatosis 2/genetics*
;
Genes, Neurofibromatosis 2
;
Oculomotor Nerve Diseases/genetics*
;
Computational Biology
;
Genomics
;
Mutation
6. Minor liver resection for hilar cholangiocarcinoma of Bismuth-Corlette type Ⅲ and Ⅳ
Enshan LI ; Yanlei SUN ; Xuejian LIU ; Qingpin TAI ; Rongfei ZHAO ; Shifang LYU ; Xiaoping CHEN
Chinese Journal of Surgery 2019;57(7):523-526
Objective:
To explore the clinical effect and safety of minor liver resection for hilar cholangiocarcinoma (HC) of Bismuth-Corlette type Ⅲ and Ⅳ.
Methods:
From May 2007 to May 2017, the clinical data of 108 patients with Bismuth-Corlette type Ⅲ and Ⅳ HC underwent hepatectomy were collected and analyzed retrospectively.There were 56 males and 52 females, aged (57.2±5.3) years (ranged 48-76 years) .Among the 108 cases, there were 51 cases of type Ⅲa, 40 cases of type Ⅲb and 17 cases of type Ⅳ. Small-scale hepatectomy (≤3 hepatectomy) was performed in 70 cases, including 8 cases of 4b segment resection, 28 cases of 4b segment+5 segment resection, and 34 cases of partial 4 segment+partial 7 segment+partial 1 segment resection. Large-scale hepatectomy was performed in 38 cases (>3 segments) , of which 30 cases were treated with 2 segments+3 segments+4 segments+1 segment, and 8 cases were treated with 5 segments+7 segments+8 segments+1 segment.